- Conditions
- Neoplasms, Neoplasm Metastasis, Non-Small-Cell Lung Cancer
- Interventions
- EMB-01
- Drug
- Lead sponsor
- Shanghai EpimAb Biotherapeutics Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 186 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • Detroit, Michigan • Canton, Ohio
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 505–528
of 1,308
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Non-small Cell Lung Cancer, Brain Cancer
- Interventions
- Tarceva (Erlotinib hydrochloride), Radiation Therapy
- Drug · Radiation
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2019
- U.S. locations
- 2
- States / cities
- Tucson, Arizona • Houston, Texas
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Tobemstomig, Pembrolizumab, Paclitaxel, Pemetrexed, Carboplatin
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 182 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 2
- States / cities
- Detroit, Michigan • Reno, Nevada
- Conditions
- Lung Cancer, Non-small Cell Lung Cancer, Metastatic Lung Cancer, Head and Neck Cancer, Metastatic Squamous Cell Carcinoma, Metastatic Head and Neck Cancer, Resectable Head and Neck Squamous-cell Carcinoma
- Interventions
- PD-1/PD-L1 inhibitor monotherapy - 4 cycles before 12:00PM, PD-1/PD-L1 inhibitor monotherapy - 4 cycles after 3 PM, PD-1 inhibitor monotherapy - 2 cycles before 12:00PM, PD-1 inhibitor monotherapy - 2 cycles after 3 PM
- Drug
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 238 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2033
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Metastatic Solid Cancers, Colorectal Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Gastrointestinal Cancer, Ovarian Cancer, Genitourinary Cancer
- Interventions
- Aldesleukin, Fludarabine, Cyclophosphamide, KRAS TCR-Transduced PBL, GRT-C903/GRT-R904
- Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 72 Years
- Enrollment
- 210 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Cabozantinib, Atezolizumab, Docetaxel
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 366 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 12
- States / cities
- Palo Alto, California • San Diego, California • Santa Barbara, California + 9 more
- Conditions
- Advanced Non-small Cell Lung Cancer, HER2 Mutation
- Interventions
- Sevabertinib, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 555 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 25
- States / cities
- Newport Beach, California • San Diego, California • San Francisco, California + 20 more
- Conditions
- Endometrial Cancer, Endometrial Cancer Recurrent, Lung Cancer Recurrent, Lung Cancer, Non-small Cell Lung Cancer Metastatic, Non-small Cell Carcinoma
- Interventions
- RGX-104, Ipilimumab, Docetaxel, Pembrolizumab, Carboplatin, Pemetrexed
- Drug
- Lead sponsor
- Inspirna, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 146 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2025
- U.S. locations
- 21
- States / cities
- Tucson, Arizona • Los Angeles, California • Aurora, Colorado + 16 more
- Conditions
- Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Non-Small Cell Lung Cancer, Hepatocellular Carcinoma
- Interventions
- Ramucirumab, MEDI4736
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 7
- States / cities
- Santa Monica, California • Baltimore, Maryland • St Louis, Missouri + 4 more
- Conditions
- Advanced Solid Tumors
- Interventions
- OSI-906
- Drug
- Lead sponsor
- Astellas Pharma Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 79 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Lung Cancer
- Interventions
- Nivolumab
- Biological
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 363 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 77
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Bakersfield, California + 70 more
- Conditions
- Non-Small Cell Lung Cancer Metastatic
- Interventions
- Durvalumab, Pemetrexed, Carboplatin
- Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Non Small Cell Lung Cancer (NSCLC), Metastases to the Brain
- Interventions
- cabozantinib
- Drug
- Lead sponsor
- Liza Villaruz, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Atezolizumab, Tiragolumab, Placebo
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 135 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 11
- States / cities
- Tempe, Arizona • Fort Myers, Florida • St. Petersburg, Florida + 8 more
- Conditions
- Non Small Cell Lung Cancer NSCLC
- Interventions
- Durvalumab, Tremelimumab, Abraxane + carboplatin, Gemcitabine + cisplatin, Gemcitabine + carboplatin, Pemetrexed + carboplatin, Pemetrexed + cisplatin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 1,186 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 16
- States / cities
- Phoenix, Arizona • Bakersfield, California • Santa Monica, California + 13 more
- Conditions
- Cancer
- Interventions
- captopril, cyclophosphamide, autologous bone marrow transplantation, peripheral blood stem cell transplantation, radiation therapy
- Drug · Procedure · Radiation
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- Not listed
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2002
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Microbiome
- Diagnostic Test
- Lead sponsor
- University of California, Irvine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Orange, California
- Conditions
- Lung Cancer, Non-Small Cell
- Interventions
- Niraparib, Pembrolizumab, Placebo
- Drug · Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 666 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 21
- States / cities
- Fullerton, California • Los Angeles, California • Lone Tree, Colorado + 18 more
- Conditions
- Leukemia, Lung Cancer, Malignant Mesothelioma, Myelodysplastic Syndromes, Primary Peritoneal Cavity Cancer
- Interventions
- WT-1 analog peptide vaccine, incomplete Freund's adjuvant, sargramostim, polymerase chain reaction, flow cytometry, immunoenzyme technique
- Biological · Genetic · Other
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- nab-paclitaxel IV, CC-486, Duravalumab
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 9
- States / cities
- San Francisco, California • New Britain, Connecticut • Athens, Georgia + 6 more
- Conditions
- Lung Cancer
- Interventions
- Itacitinib, Osimertinib
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2025
- U.S. locations
- 23
- States / cities
- La Jolla, California • San Francisco, California • Whittier, California + 19 more
- Conditions
- Male Breast Carcinoma, Prostate Adenocarcinoma, Recurrent Breast Carcinoma, Recurrent Non-Small Cell Lung Carcinoma, Recurrent Prostate Carcinoma, Stage IV Breast Cancer, Stage IV Non-Small Cell Lung Cancer, Stage IV Prostate Cancer
- Interventions
- Stereotactic Body Radiation Therapy (SBRT)
- Radiation
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2022
- U.S. locations
- 74
- States / cities
- Birmingham, Alabama • Peoria, Arizona • Tucson, Arizona + 66 more
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Itacitinib, Pembrolizumab
- Drug · Biological
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Lung Cancer
- Interventions
- high performance liquid chromatography, pharmacological study, radionuclide imaging, single photon emission computed tomography, radiation therapy, yttrium Y 90 anti-CEA monoclonal antibody cT84.66
- Other · Procedure · Radiation
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2018
- U.S. locations
- 1
- States / cities
- Duarte, California